Back

How Long Does It Take to See Results with GLP-1 Agonists like Mounjaro or Wegovy?

By 
Dr Amit Kumar Singh
 on 
Nov 19, 2024
 • 
5
 min read

Many people embarking on a weight management GLP-1 (Glucagon-like peptide-1) agonists often experience a mix of anticipation and frustration. It’s natural to feel a sense of urgency when it comes to health, especially in a world where immediate results seem to dominate the narrative.

You might be wondering, "Why isn’t the scale moving as quickly as I’d hoped?" or "When will I start to feel the benefits of this medication?" These questions can be disheartening, especially when you’re putting in the effort to make lifestyle changes and stick to your treatment plan. It’s easy to feel like progress is just out of reach, like you're on a treadmill, running hard but not getting anywhere.

However, amid the frustration, there is a glimmer of hope. Understanding the timeline for seeing results with GLP-1 agonists can transform your experience from one of impatience to a journey of patience and self-discovery. While every person’s experience is unique, many find that with the right mindset and realistic expectations, progress is not just possible—it’s achievable. In this article, we’ll delve into what you can typically expect when using GLP-1 agonists, helping to illuminate the path ahead and reminding you that meaningful change often takes time. Let's explore this journey together!

Timeframe for Weight Loss Results with GLP-1 Agonists

GLP-1 receptor agonists, such as Wegovy (semaglutide) and Mounjaro (tirzepatide), are designed to regulate blood sugar and appetite by enhancing insulin release, reducing glucagon, and slowing digestion. By promoting feelings of fullness, these medications support gradual and sustained weight loss, making them effective tools for managing obesity, diabetes, and overall metabolic health.

Weight loss with GLP-1 agonists typically occurs in three distinct phases, each with its own timeframe:

Weight Loss Phases with GLP-1 Agonists:

  1. Initial Phase (Weeks 1–4): Patients often begin to notice weight loss within the first 2 to 4 weeks of treatment. Clinical studies have shown that individuals can experience a weight reduction of approximately 2–4% of their total body weight during this period.
  2. Continued Weight Loss (Months 2–6): With ongoing treatment, weight loss continues at a steady pace. By the 12-week mark, patients may achieve a total weight loss of around 5–10%.
  3. Maintenance Phase (Beyond 6 Months): After six months, weight loss typically plateaus. Sustained use of GLP-1 agonists, combined with lifestyle modifications, helps maintain the achieved weight loss. Long-term studies indicate that patients can maintain a weight loss of approximately 10–15% of their initial body weight after one year of treatment. 

Strategies to Overcome Plateaus

‍To navigate these plateaus, several strategies can be employed:

  • Adjusting Dosage: Consulting with healthcare providers to potentially adjust the dosage of GLP-1 agonists may enhance their effectiveness.
  • Incorporating Lifestyle Modifications: Engaging in regular physical activity and reassessing dietary habits can help break through plateaus. For instance, increasing protein intake has been shown to reduce hunger and improve satiety, which may aid in overcoming weight loss stalls.

Long-Term Weight Loss

Continued treatment with GLP-1 agonists has been associated with sustained weight loss over time. Clinical trials have shown that individuals who maintain adherence to their medication regimen can achieve significant long-term weight reductions. For example, participants in studies have reported maintaining an average excess weight loss of around 11% over a year following treatment initiation.

Importance of Adherence and Lifestyle Changes: Long-term success in weight management relies heavily on adherence to medication and lifestyle modifications. Maintaining a balanced diet, engaging in regular physical activity, and monitoring caloric intake are essential components for sustaining weight loss achieved through GLP-1 agonist therapy. Research suggests that consistent engagement with healthcare professionals for support can further enhance adherence rates and overall success in maintaining weight loss.

Factors Affecting Weight Loss Results with GLP-1 Agonists

Individual Variation

Individual characteristics such as metabolism, genetics, and baseline weight significantly influence weight loss outcomes when using GLP-1 agonists. For instance:

  • Metabolism: Individuals with a higher metabolic rate may experience faster weight loss compared to those with slower metabolism. A study published in Diabetes Care indicated that metabolic factors could account for variations in weight loss among patients treated with liraglutide, where participants with a higher resting metabolic rate lost more weight over 26 weeks.
  • Genetics: Genetic predispositions can affect how individuals respond to GLP-1 therapy. Research has shown that polymorphisms in the GLP-1 receptor gene may influence the effectiveness of treatment, affecting both appetite regulation and insulin sensitivity.
  • Baseline Weight: Baseline weight also plays a crucial role; individuals with higher initial weights tend to experience greater absolute weight loss. For example, a clinical trial involving semaglutide reported that participants with a baseline body mass index (BMI) over 35 kg/m² lost an average of 15% of their body weight after 68 weeks, while those with lower baseline weights lost less in relative terms.

These factors can impact not only the rate but also the extent of weight loss achieved through GLP-1 agonist therapy.

Which is better? Mounjaro or Wegovy? 

When considering GLP-1 agonists for weight loss, it's natural to wonder how Mounjaro and Wegovy compare in terms of effectiveness. Both medications have shown significant results in clinical trials, but the timeline and extent of weight loss can vary between the two.

To help visualise the expected weight loss at different doses, let's look at this comparative table:

‍

‍

‍

These percentages represent average weight loss from baseline over a 68-72 week period, based on the SURMOUNT-1 trial for Mounjaro and the STEP-1 trial for Wegovy.

As we can see, Mounjaro tends to show higher weight loss percentages across all doses compared to Wegovy. At the highest doses, Mounjaro users experienced an average weight loss of about 22.5% of their initial body weight, while Wegovy users saw an average loss of about 15%.

Lifestyle Factors

Combining GLP-1 agonist therapy with lifestyle modifications is essential for maximising weight loss and improving overall health. Studies suggest that:

  • Dietary Changes: Implementing a balanced diet can enhance the effects of GLP-1 agonists. A randomised trial found that patients who adhered to a low-calorie diet while on liraglutide lost significantly more weight than those who did not modify their diet, averaging an additional 3 kg over six months.
  • Physical Activity: Regular exercise complements the appetite-suppressing effects of GLP-1 agonists. A study on the long term effect of semaglutide demonstrated that individuals who engaged in regular physical activity while on semaglutide experienced greater weight loss (up to 20%) compared to those who did not exercise.

Tips on Improving Weight Loss with GLP-1s 

While GLP-1 medications like Mounjaro and Wegovy are highly effective for weight loss, their impact can be significantly enhanced by making certain lifestyle and behavioural adjustments. Here are some expert-backed tips to optimise your weight loss journey:

1. Follow a Balanced, Nutrient-Dense Diet

  • Focus on whole, unprocessed foods like lean proteins, whole grains, fruits, and vegetables.
  • Limit added sugars, refined carbs, and saturated fats, which can slow down your progress.
  • Incorporate high-fibre foods to promote satiety and improve gut health.

2. Stay Consistent with Medication

  • Take your medication exactly as prescribed by your healthcare provider.
  • Maintain your dosing schedule to ensure optimal blood sugar regulation and appetite control.

3. Hydrate Properly

  • Aim to drink at least 8–10 glasses of water per day
  • Staying hydrated can help reduce hunger cues often mistaken for thirst.

4. Incorporate Regular Physical Activity

  • Combine aerobic exercises (e.g., walking, cycling) with strength training for maximum results.
  • Start with small, achievable goals if you’re new to exercise, and gradually increase intensity.

5. Track Your Progress

  • Keep a journal of your meals, physical activity, and weight changes.
  • Use apps or wearable devices to monitor calorie intake and activity levels.

6. Prioritise Sleep

  • Aim for 7–9 hours of quality sleep per night.
  • Poor sleep disrupts hormones related to hunger and satiety, potentially hindering weight loss.

7. Manage Stress Effectively

  • Practice stress-reducing techniques like mindfulness, meditation, or yoga.
  • Chronic stress can lead to emotional eating and weight gain.

8. Set Realistic Expectations

  • Understand that sustainable weight loss takes time and may not happen at the same pace for everyone.
  • Celebrate small milestones to stay motivated.

9. Work with a Healthcare Professional

  • Regularly check in with your healthcare provider or a registered dietitian.
  • They can help adjust your treatment plan, provide personalised dietary advice, and address any side effects.

10. Build a Support System

  • Engage with friends, family, or support groups who can encourage and motivate you.
  • Share your goals and progress to create accountability.

Conclusion

GLP-1 agonists offer a powerful tool for weight loss and diabetes management, but their success depends on a combination of personalised treatment and healthy lifestyle choices. Individual factors such as genetics, metabolism, and baseline weight influence outcomes, while a balanced diet and regular exercise significantly enhance results. Consulting with a healthcare professional ensures a tailored approach, optimising both safety and effectiveness for long-term success.

Frequently Asked Questions

1. What are GLP-1 agonists, and how do they work for weight loss?
GLP-1 agonists are medications that mimic the hormone GLP-1, which helps regulate appetite and insulin. They can promote weight loss by enhancing feelings of fullness, reducing hunger, and slowing down gastric emptying, which can lead to lower calorie intake.

2. Are GLP-1 agonists safe for women in the UK?
Yes, GLP-1 agonists are generally considered safe for women, but it’s essential to consult with a healthcare professional to discuss any individual health concerns, medical history, or potential side effects.

3. Can I take GLP-1 agonists while pregnant or breastfeeding?
GLP-1 agonists are not recommended during pregnancy. It’s crucial to discuss your options with your healthcare provider.

4. How much weight can I realistically expect to lose while on GLP-1 agonists?
Weight loss can vary widely among individuals, but many people lose between 5% to 10% of their body weight over six months to a year. Factors such as diet, exercise, and individual metabolism play significant roles.

5. Are there any specific dietary recommendations while on GLP-1 agonists?
Focusing on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins is advisable. Staying hydrated and avoiding high-calorie, low-nutrient foods can also help maximise results.

6. Where can I access GLP-1 agonists in the UK?
GLP-1 agonists are available through prescription from SheMed Healthcare. Speak to our specialist and book your blood test for GLP-1 eligibility.

References

‍

Share this post

https://ea-wip-shemed-uk.webflow.io/blog/how-long-does-it-take-to-see-results-with-glp-1-agonists-like-mounjaro-or-wegovy

Related Articles

Weight Loss

Understanding Tirzepatide: The Active Ingredient in Mounjaro

By 
Dr Amit Kumar Singh
•
100
 min read

Mounjaro is a new medication developed by Eli Lilly that contains the active ingredient tirzepatide. It was originally designed to help people with type 2 diabetes manage their blood sugar levels. Mounjaro is administered as a once-weekly injection using a self-injection pen, typically into the abdomen, thigh, or upper arm. In the UK, tirzepatide (Mounjaro) has been approved for use by the Medicines and Healthcare products Regulatory Agency (MHRA).

Besides helping with blood sugar, Mounjaro has also been found to be very effective at helping people lose weight. This is why you might have heard it called a "weight loss jab" in the media.

  • How you take it: You inject Mounjaro once a week. Your doctor will usually start you on a small dose and slowly increase it over time. This helps your body get used to the medicine and can lower the chance of you feeling sick.

How it Works:

Mounjaro is like a "twin hormone" medicine. It acts like two natural gut hormones, GLP-1 and GIP. These hormones help control blood sugar and appetite.

  • It helps your body release more insulin when needed and lowers sugar from your liver, improving blood sugar control.
  • It makes you feel fuller sooner and for longer, helping you eat less.
  • Working on both GLP-1 and GIP is thought to be why it can lead to greater weight loss than medicines that only use GLP-1 (like Semaglutide in Ozempic/Wegovy).

What is it Used For?

  1. Type 2 Diabetes: Mounjaro lowers blood sugar effectively, often helping patients reach better levels (lower HbA1c). It's used alongside diet and exercise, sometimes with other diabetes medicines, typically when standard treatments aren't enough, especially if weight loss would help.
  2. Weight Management: In studies, people using Mounjaro lost a significant amount of weight, often averaging 15-20% of their body weight over about 1 to 1.5 years. It's approved for adults with obesity (high BMI) or those with a lower BMI and a weight-related health problem.

Access in the UK:

  • NHS: Mounjaro is available on the NHS for type 2 diabetes if you meet certain criteria. For weight loss, NHS access is starting gradually through specialist clinics for adults with a very high BMI and multiple weight related health issues.
  • Private: You can also access Mounjaro privately through weight loss clinics, pharmacies or online services like ours if you meet the medical criteria. SheMed operates a weight management programme specifically tailored for women, which includes the potential prescription of GLP-1 medications such as Mounjaro and Wegovy, provided the individual meets their medical criteria.

Mounjaro vs. Semaglutide (Ozempic/Wegovy):

Both are effective weekly injections. Semaglutide works on GLP-1 while Mounjaro works on both GLP-1 and GIP. Studies suggest Mounjaro may lead to slightly more weight loss on average. But choice of drug depends on a number of factors and is very individual.

Side Effects and Safety:

Common side effects are usually mild stomach issues (nausea, vomiting, etc.) that often improve over time. Because it affects appetite, you'll feel less hungry. If you take other diabetes medicines, your doctor might adjust doses to prevent low blood sugar.

Serious side effects are rare, but contact a doctor immediately for severe tummy pain, persistent vomiting, allergic reactions, or worrying mood changes.

Important Note: Mounjaro works best with healthy eating and exercise. If you stop Mounjaro, appetite and weight can return if lifestyle changes aren't maintained.

Check our healthcare support page to see if Mounjaro could be a suitable option for you based on your health needs and the latest criteria.

FAQs 

1. How is Mounjaro administered?
Mounjaro is given as a once-weekly injection. Your healthcare provider will guide you on the correct dosage and administration technique.

2. Can I use Mounjaro if I’m pregnant or breastfeeding?
No, tirzepatide is not recommended during pregnancy or breastfeeding, as its safety in these situations has not been established. If you are planning to conceive or are breastfeeding, discuss alternative options with your doctor.

3. How long does it take to see results with Mounjaro?
While individual results vary, many users begin noticing changes within a few weeks. Maximum benefits are typically observed after several months of consistent use, alongside dietary and lifestyle adjustments.

References

  1. MotherToBaby. (2024). Tirzepatide (Mounjaro®, Zepbound®) - Mother To Baby | Fact Sheets. https://www.ncbi.nlm.nih.gov/books/NBK605070/
  2. Watanabe, M., & Hasegawa, Y. (2021). Tirzepatide in adults with obesity and type 2 diabetes. New England Journal of Medicine, 385(11), 1046-1056. https://doi.org/10.1056/NEJMoa2107519
  3. Kahn, S. E., & Florez, J. C. (2023). Tirzepatide: A dual GLP-1 and GIP receptor agonist for type 2 diabetes management. PMC, 11543192. https://pmc.ncbi.nlm.nih.gov/articles/PMC11543192/
  4. Kahn, S. E., & Florez, J. C. (2023). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/36751934/
  5. Nauck, M. A., & Quast, D. R. (2020). Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide: A review of their roles in obesity and type 2 diabetes. Endocrine Reviews, 41(3), 1-24. https://pubmed.ncbi.nlm.nih.gov/32459834/‍
  6. Kahn, S. E., & Florez, J. C. (2020). Tirzepatide: A novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for type 2 diabetes management. Endocrine Society. https://www.ncbi.nlm.nih.gov/books/NBK605070/
Weight Loss

Mounjaro Outperforms Wegovy in Major Weight-Loss Drug Trial

By 
Dr Amit Kumar Singh
•
100
 min read

A groundbreaking clinical trial has revealed that Mounjaro (tirzepatide) leads to greater weight loss than its rival Wegovy (semaglutide), offering new hope for people struggling with obesity.

Head-to-Head Results: Mounjaro vs Wegovy

The study, presented at the European Congress on Obesity and published in the New England Journal of Medicine, compared the two most talked-about weight-loss injections. Over 72 weeks, participants taking Mounjaro lost an average of 20% of their body weight, compared to 14% for those on Wegovy. That’s a significant difference, especially for those with a lot of weight to lose.

Key Findings:

  • 32% of Mounjaro users lost at least a quarter of their body weight, compared to 16% on Wegovy.
  • Waistlines shrank more: Mounjaro users lost an average of 18cm from their waists, while Wegovy users lost 13cm.
  • Health improvements: Mounjaro also led to better blood pressure, blood sugar, and cholesterol results.
  • Similar side-effect profiles for both drugs.
  • Women tended to lose more weight than men on both medications.

How Do These Medications Work?

Both Mounjaro and Wegovy help people feel full, reducing appetite and encouraging the body to burn stored fat. The key difference is that Wegovy mimics one appetite-control hormone, while Mounjaro targets two, which may explain its superior results.

Mounjaro and Wegovy: Availability and Eligibility in the UK

Both Mounjaro and Wegovy are available for weight management in the UK through both the NHS and private clinics. Here’s what you need to know about who can access them and how.

NHS Eligibility Criteria

Both medications are available on the NHS, but only for people who meet specific criteria:

  • Adults with a BMI of 35 or above and at least one weight-related health condition (such as high blood pressure, cardiovascular disease, or osteoarthritis).
  • Adults with a BMI of 30 or above who qualify for referral to a Specialist Weight Management Service (SWMS) and have not succeeded with other weight loss methods.
  • Some groups, such as certain minority ethnic backgrounds or those with cardiovascular disease, may qualify with a BMI as low as 27.5.

Private Prescription Criteria

For those seeking treatment privately, the requirements are less strict:

  • BMI of 30 or above, or BMI of 27 or above with a weight-related health condition or from certain ethnic backgrounds.
  • Patients must complete an online or in-person consultation, including questions on weight, medical history, and current medications.
  • New regulations require verification of identity and medical suitability, often with GP input or supporting records.

Estimated Monthly Costs


Customers seeking access to weight loss treatments like Mounjaro and Wegovy can conveniently receive private prescriptions through online clinics such as SheMed Healthcare. SheMed specializes in providing healthcare services tailored for women, including a dedicated weight loss programme.

Here is a breakdown of the programme's pricing:

  • Starting Price: £99 for the initial dose.
  • Includes: This initial cost covers a health screening, which involves a blood test to ensure the treatment is safe and appropriate.
  • Subsequent Doses: Later doses are priced at £159 each.

Conclusion

This major trial confirms Mounjaro's significant edge over Wegovy, demonstrating superior weight loss and better health outcomes for individuals with obesity. Both medications represent powerful advancements in weight management and are available in the UK via NHS and private pathways, offering promising new options for those seeking effective medical treatment. If you have any questions about these medications or weight loss options, please visit the SheMed Support website for more information.

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.